About: COVID-19 OUTCOMES IN MS: EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTER

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 OUTCOMES IN MS: EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTER Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 OUTCOMES IN MS: EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTER
Creator	Abou-Fayssal, Nada Charvet, Leigh Fernandez-Carbonell, Cristina Gottesman, Malcolm Gutman, Josef Howard, Jonathan Keilson, Marshall Kister, Ilya Krupp, Lauren Parrotta, Erica Saha, Valerie Wolintz, Robyn Charlson, R Dnp, Carrie Ryerson, Lana
source	MedRxiv
abstract	Objective: Report outcomes on patients with Multiple Sclerosis (MS) and related disorders with COVID-19 illness. Methods: From March 16 to April 30th, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center (MSCC) were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by a review of in-patient hospital records. Results: We identified 76 patients (55 with relapsing MS of which 9 had pediatric-onset;17 with progressive MS; and 4 with related disorders). 37 underwent PCR testing and were confirmed positive. Of the entire group, 64 (84%) patients were on disease-modifying therapy (DMT) including anti-CD20 therapies (n=34, 44.7%) and sphingosine 1-phosphate receptor modulators (n=10, 13.5%). The most common COVID-19 symptoms were fever and cough, but 21.1% of patients had neurologic symptom recrudescence preceding or coinciding with the infection. A total of 18 (23.7%) were hospitalized; 8 (10.5%) had COVID-19 critical illness or related death. Features more common among those hospitalized or with critical illness or death were older age, presence of comorbidities, progressive disease, and a non-ambulatory status. No DMT class was associated with an increased risk of hospitalization or fatal outcome. Conclusions: Most MS patients with COVID-19 do not require hospitalization despite being on DMTs. Factors associated with critical illness were similar to the general at risk patient population. DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1101/2020.05.12.20094508
has license	medrxiv
sha1sum (hex)	d23a23131e4abaf6176686e6897e4193c5c9fcfc
schema:url	https://doi.org/10.1101/2020.05.12.20094508
resource representing a document's title	COVID-19 OUTCOMES IN MS: EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTER
resource representing a document's body	covid:d23a23131e4abaf6176686e6897e4193c5c9fcfc#body_text
is schema:about of	named entity 'OUTCOMES' named entity 'CENTER' named entity 'S1P' named entity 'ICU' named entity 'infection' named entity 'IVIG' named entity 'peer review' named entity 'COVID-19 pandemic' named entity 'COVID' named entity 'fatigue' named entity 'neuropathy' named entity 'fingolimod' named entity 'peer review' named entity 'S1P' named entity 'COVID' named entity 'ethnicity' named entity 'glatiramer acetate' named entity 'DMTs' named entity 'inflammatory' named entity 'COVID-19' named entity 'ocrelizumab' named entity 'coronary artery disease' named entity 'immunosuppressive' named entity 'COVID-19 disease' named entity 'natalizumab' named entity 'Institutional Review Board' named entity 'interferon beta-1b' named entity 'COVID' named entity 'IgG' named entity 'diabetes' named entity 'pediatric' named entity 'radiographic' named entity 'comorbidities' named entity 'hypertension' named entity 'venous thromboembolism' named entity 'missing data' named entity 'steroids' named entity 'infection' named entity 'convenience sample' named entity 'siponimod' named entity 'downregulating' named entity 'older age' named entity 'COVID' named entity 'medRxiv' named entity 'United States' named entity 'p=0.01' named entity 'observational study' named entity 'Long Island' named entity 'relapsing-remitting' named entity 'COVID' named entity 'peer review' named entity 'ocrelizumab' named entity 'neurological symptoms' named entity 't-test' named entity 'Asian' named entity 'NYU School of Medicine' named entity 'COVID' named entity 'neurosarcoidosis' named entity 'hypertension' named entity 'glycoprotein' named entity 'immunosuppression' named entity 'comorbidities' named entity 'Anti-CD20' named entity 'peer review' named entity 'disability' named entity 'χ2 test' named entity 'risk factors' named entity 'anti-CD20' named entity 'COVID' named entity 'COVID-19' named entity 'critically ill'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software